Intravitreal Tissue Plasminogen Activator in the Management of Central Retinal Vein Occlusion

Abstract

Our data suggest that intravitreal tPA injection may have a beneficial role in the management of CRVO when used within a few days of the onset of symptoms in patients with no angiographic evidence of severe capillary nonperfusion even if initial visual acuity is 20/200 or worse.